JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - GUARDANT HEALTH INC
Okay, great. We're going to kick it off. I'm Tucker Peterson for the Life Science Team. It's my pleasure to introduce Garden. Welcome. Maybe a quick high level just to kind of recap on the quarter. Obviously, a lot of momentum heading into 27. Just quick takeaways coming out of 3Q and the messaging, you know, for next year. Yeah, no, I mean, we continue to, I think, operate at a very high level. It's really nice where you have essentially all our products really sort of hitting their stride. We have of garden 360 continuing to sort of outperform from a sort of late stage therapy selection point of view. We hit nearly 30 percent volume growth again. We have our MRD tests reveal growing well over 100 percent year over year, so it's really nice to see that continuing to do very well. And then I think with SHIELD seeing that, you know, grow, I mean, I think over 300%, or it's 3x in terms of the volumes, and really continuing to be one of the fastest diagnostics, one of them are successful diagnostic launches outside of COVID. So we couldn't ask for anything more. It's been really great. Maybe just thinking about G360, liquid growth, obviously you've got a decent market, you're getting shares, as you've talked about. Well, maybe just talk about some of the bigger drivers for next year on G360. Yeah, there's a few. You know, we will sort of have the complete launch of Garden 360, Liquid CDX in terms of the FDA-approved version, you know, hopefully next year. That should further catalyze volume growth. We just launched last week another crop of smart apps on the platform, 11 new apps, Some of them, you know, pretty groundbreaking in terms of immune checkpoint inhibitor prediction, being able to sort of characterize PD-L1 in blood. So a lot of things we've been working on that, you knows, took a lot of data analysis and so on to be able to implement and develop and launch. And so that's been exciting. We have the recent sort of approval of EdCama, the sort of Serena 6 output for breast cancer. That, you know, I think will continue to sort of catalyze volume growth in next year as more breast cancer patients get tested. And then, you Know, obviously we'll have probably, you Now, other smart app launches next year, as well. Male Speaker 1 and I think, yeah, you've talked maybe 30, 40 apps, you know, in the pipeline here. Male Speaker 2 Yeah. Male Speaker 3 I mean, how quickly do those start to have an impact when you roll them out? Male Speaker 4 Pretty quickly. It takes some time to sort of educate the market and go through sort of the capabilities and the ins and outs of each of those apps. But if you think about it, you now, these apps become sort of like the next iPhone launch in some ways where, you know, physicians wait for them. They want to see that the test is changing. There's always something new that physicians can look forward to because fact of the matter is, as good as sort of oncology has gotten from a precision medicine point of view, there was always, you now, patients that essentially need more options and need greater utility. And that's what these apps continue to provide. And what's really exciting is that we now have hundreds of thousands of patients that are in the sort of real-world evidence database with EMR data, with claims data, and we're really able to develop apps that we could never before because the ones we're developing need hundreds of thousands of, you know, patients with outcome data and so on to actually develop prediction and some of the other biomarker stuff. We're doing things with ADCs and so On. So it's really, I would say, the fruition of what we all expected precision medicine to be or precision oncology to be is finally coming to bear. And just thinking about serialization, you know, on liquid and kind of repeat testing, you've obviously got therapy monitoring emerging as a pretty big category. Can you just talk to where you think that's headed? Yes, I think, you Know, one of the things that continues to be underestimated, I I think, is how large the market is in therapy selection plus therapy response monitoring. And when you think about it, there's, you know, close to a million late-stage patients. Many of them will need certainly a tested diagnosis, perhaps two tests, a tissue test and a liquid test. And essentially, you knows, those patients want to be sort of monitored in terms of is this therapy working or not. They may have toxicities with those therapies, the physician may be uncertain whether they need to push through because the tumor, the cancer is responding, and so there are a lot of use cases where therapy monitoring really makes a lot of sense, and if you think about those million patients getting multiple therapy monitoring tests, that's millions of tests, sort of testing opportunity in the U.S. And then, you know, on top of that is the fact that patients should be getting genetic profiling, genomic profiling at every progression. The reason the cancer comes back is because the cancer's changed, it's evolved in terms of its tumor genomic profile, and that's where sort of another GARDEN360 can come in and help the physician with hopefully more options for that patient. And, you know, early days on ESR-1 with CAMI, right, FDA approval. Maybe just talk about what you're seeing from physicians so far in terms of, you know, repeat and serial testing there. Yeah, it's still early. A lot of patients are just getting their first test in this series. But we're certainly seeing, you see, an uptick of breast volumes. And I think so far so good in termsof the launch. But there's more education required. And we've been coordinating, obviously, with AZ and with advocacy groups and so on and are making good progress there. And then I guess, you know, historically there was the tissue-liquid debate. You know, now with tissue submitted to FDA, I guess how do you think about owning both modalities going forward? Yeah, we're really excited about the progress we've made with our tissue test. We believe, you Know, it is now a best-in-class product. It's the one test that essentially covers what I call three legs of the stool genomics. transcriptomics and methylation. And so it really is a very comprehensive test now. But it also fits in line with the challenges of the standard of care. It is able to use a lot less tissue than other tests. Andso we have, you know, very low Q and S rates with that modality. We've seen, I think, the biggest growth, biggest sequential growth we've ever seen in tissue from Q2 to Q3. And I think it bodes really well for, I think, increased market share in the coming years, especially when we fully launch Garden360 Liquid CDX. I think we'll be able to catalyze further growth. The other thing we did was we also submitted for FDA approval for Garden360 tissue. We should get that, you know, hopefully sometime next year. We think that'll also sort of be a growth driver for us. And attach rate longer term, how do you think about that? Yeah, I think the attach rate, a lot of the growth we've seen is counterintuitively has been standalone tissue, which I think is kind of exciting. It shows that the test sort of stands on its own two feet and is something that physicians are sort of coming to and ordering. But as we sort of fully launch the CDX on the liquid side, then I think there's an opportunity for that attachment rate to go much higher. And we touched on response monitoring earlier. I guess does this become a distinct market from traditional post-surgical MRD in the long run, or does the distinction between therapy response monitoring and MRD eventually disappear as clinicians are using CT? Yeah, if you go really long term, we think the whole market sort of converges where a lot of the drugs that are used in the metastatic setting only sort of become used much earlier. The whole sort of continuum merges into one. But in the short term, the market of therapy response monitoring is really closely linked with therapy selection, and it's why I think we have a sort of prime place in the market given that we are the leading company in CGP right now. And then on Ultra, I know you've launched with Pharma, you know, clinical launch by the end of the year. I guess, how do you think about that as, you Know, replacement upgrade cycle for, you know, existing reveal volumes versus, you know, pushing, you know, into kind of in newer markets? Yeah, so we see there's an opportunity where there are qualities that are acquired for sort of, you know, both tests for a subset of patients. When you think about the tissue-free sort of MRD side of the picture, there is a need for speed, for, you know, getting results quickly, for getting results without the need for tissue, and for a wider catchment in terms of really detecting tumors that, you know, may be different than what was taken out in terms of second primaries or heterogeneity that's there. And then at the same time, you I think there's an opportunity and obviously a market for tumor-informed, especially for ultra-sensitive tests that can go really, really deep. And so yeah, I think we have a plan to basically try to meet the market where it is in terms of making sure that we can essentially hit both sort of use cases and so on with the portfolio that we have between Reveal and Reveals Ultra. I would say maybe stay tuned for, you know, how we roll that out. And same answer on data. Stay tuned. We'll see if we get that in a lot. Oh, the data? So, yeah, we are currently running thousands of, you know, samples. We have a very, I think, advanced data plan in terms of developing clinical validity studies for all of the major tumor types. And it's something that we're working on, and obviously, as that data is ready, we're very excited to present. Maybe just shifting over to Shield, 100 million covered lives, 83,000 tests in the third quarter. Just talk a little bit about what's left in terms of Salesforce expansion, penetrating new physician accounts, and securing additional reimbursement wins. You've got a lot of it. Yeah, we are very excited with the performance of the team. We are proud of it, and still we are just scratching the surface. When we are looking at, you know, even unscreened patient population, there are 54 million of them, like 17, 18 million annual testing opportunity. And right now, maybe even in terms of run rate in Q3, we are maybe testing a third of a million. So still there is a lot of runway left. In terms of commercial infrastructure, we have still north of 400 people in terms OF sales rep, a little bit higher than that. And in our steady state number is 600 to 700. We are going to continue to scale as we go to 2027. We are expecting a sizable class to start the market early next year. DTC, our national DTC and influencer strategy, we've been very pleased with some of the pilot results that we got. We launched it late Q1. We measured it really in Q2, and the KPIs are fantastic, and we have a lot of room to flex on investment on the national DDC. So as we go to next year, we are expecting to generate more gross profit, and we are going to reinvest some of the additional gross profit into further build-out of Salesforce and national DTCs. Lastly, maybe I just mentioned this 100 million covered lives. It's really opening up this younger patient population testing for us. Previously, we've been focused on reimbursable cases, and now this reimbursement wins, which came much faster than what we expected, could increase the depth of ordering in the accounts that we are in. And just, yeah, the mechanics, you've got United on board, Cigna, Anthem. I mean, just in terms of how that will play out, is it volumes in the first half of the year, ASPs contributing in the second half? Is that the right way to think about it, just In terms of time to contract? Yeah, maybe I mentioned some words about volume, and then I asked Mike to talk about ASPs. so you know um united started in august like you know carillon is in effect actually last week and then the rest would be effective early next year in january so really like you notice the 2027 um volume boost story for us we are very uh excited about that opportunity but it's gonna take some time for us to build some kind of collection history on the asp yeah yeah i mean just to re-emphasize i think you know initially we'll have the positive coverage we'll start getting paid by these pays in fact we've started to see united payers now but when you're out of network you know that payment can can vary um so uh it'll take us time to see you know a consistent history of payment it'll takes time to contract with each of these payers so yeah as you mentioned Tyco probably back half of 27 we'll start to be able to you know accrue accrue the revenue on the commercial side and we'll see the revenue the revenue impact then and and on the margin side you actually had a nice step down at cogs and in 3q I know there's still stuff to come on on the automation front just talk a little bit about you know the roadmap yeah you know the the progress we've made on shield cogs where we're incredibly proud of you know when we launched just over two years ago uh cost per test was over a thousand dollars with volume we've driven that down uh q2 it was just over 400 and then at the start of q3 we got this fda approval for low cost high throughput shield so that went live in the in the lab at the starter q3 and our cogs over that quarter came down from over 400 to 330 so a significant step down and then as we look forward you know we've set this target of $200 cost per test by the end of 2028 so we're well on track for that volume increasing volumes going to continue to to help us there we're also investing heavily in automation that will need to go through an FDA approval process and we think that'll be sometime late 27 but when that comes through obviously we're about to take out a lot of labor costs in the operations and we'll see another nice step down in cost per tests so again yeah we're we're well on track to a $200 cost per test and I guess just back to the pair dynamic as we think about commercial ramping you know how do you think about the remaining friction around you know cost-sharing you know co-pays remaining out-of-pocket how do you think about that so right now what we are seeing actually is vast majority of our patient do not have any kind of financial responsibility and you know And when you're looking at especially preventive services, even, you know, sometimes $20, $25 out-of-pocket cost contribution could really impact utilization of that preventative services. So we are in a good position, but in order for the rest of the patients to really have access to $0 out-the-pockets, we need to wait for USPSCF guideline inclusion that would make this really a broad access for everybody. I guess on that note what are you expecting we're supposed to hear something this month on USPSDF yeah what's kind of just the latest latest thinking there we are monitoring the situation very closely like you know the positive thing is like the some new members have been selected for a first time actually I think it's for a very really there are some specialists on the USPSF panel like one GIA specialist you know notably and you know based on some of the HHS commentary to media. Like, they're supposed to meet in November, and we are monitoring the situation to see if that meeting happens or not. But the rule of USPSC has kind of evolved. It used to be the case that really Task Force recommendation was a gating function for these screening tests. Now, still, it's a very important accident when you're thinking about $0 out-of-pocket when you are talking about quality score. But look, when you're looking at 80% covered lives that we have now, when you're even looking at some state-level legislation like what has happened in Pennsylvania that brought in access to shield blood testing at zero cost to lives over there, we have a lot of business to grow while we are waiting for task force and still task force recommendation is an important catalyst. yeah so I guess in terms of the relative importance of USPS TF2 versus kind of what we saw a cold are back in the day it just like that's changed yeah yeah maybe you could spend a minute on biopharma some of the initiatives there you know on the data side yeah it's a you know we are gonna probably hit something like one exabyte of data in a couple years so it's an area that we've invested heavily in the first sort of aspect of that data has been making our tests better all these apps going to multi-cancer multi-disease and so on is couldn't have been done without having hundreds of thousands of sort of patient data and outcomes but now we're starting to work with our biopharma partners and that's been probably the single fastest growing segment of our biopharm and data business is the work we're doing with biopharma obviously a lot of the work that we're outside of that is helping them with their trials, testing, you know, patients, a lot of the sort of monitoring of those patients in trial as a sort of surrogate endpoint for those trials has been another area of growth for us as well. And I guess, yeah, how material could biopharma be over the next couple of years? Yeah, I mean, I think we can, you knows, continue to grow it pretty nicely. As I said, the data part of it is growing quickly. You're seeing in almost every pharma presentation this early treatment response dynamic where you can test patients in trials at four weeks, eight weeks, 12 weeks, and get an early read in terms of the efficacy of that drug that may predict better than some of the radiographic markers and data in some of those trials. And so we're seeing that grow very heavily. We're seeing, essentially, a lot of drugs that don't have genomic, traditional genomic biomarkers. We're able to come in with our methylation data, epigenomic data, and help them sort of segment patients much more nicely. So, yeah, we see a lot sort of growth opportunities in the coming years. We started to get more questions beyond oncology as well. Can you talk a little bit about your strategy beyond the oncology portfolio? Yeah, so I think we are very excited that some of our products, and maybe I give the example of S.H.I.E.L.D., can detect other diseases beyond oncology. And the bridge is really the biomarkers that we are testing, the substrates that we're testing, are beyond oncologist biomarker. biomarkers. We have databases just based on the scale of SHIELD and REVEAL. We have databases at Garden that for 500 diseases and sub-diseases, we have correlated epigenomic profile in those diseases. We are seeing some genuine, you know, very strong proof of concept about a blood test, same, let's say, SHIELDS blood test that not only can detect multi-cancer detection, can look at liver disease, can look at kidney disease, can look other diseases. So the future that we are foreseeing is in a few years when the patient goes for annual checkup or a simple blood test, you can screen that patient for multiple diseases. And that's a huge unmet need. When we are looking at some diseases with a significant issue in underdiagnosis, this blood test can bring the patient to the journey of multi-disease detection and add significant amount of value. Mike, one for you on just kind of the free cash flow break-even target, just thinking about kind of what are the biggest swing factors here between ASPs, COGs we talked about, OPEX? Yeah, I mean, firstly, from a free cash-flow perspective, we've been targeting Q4 of 2027 as the break-Even target. we remain well on track for that. You know, I think if you look at the business excluding screening, that became breakeven last year. It's positive cash flow this year. It's going to be incremental positive cash floor in 2027. And screening, you know, we've been investing heavily on the sales and marketing side for the last couple of years. That will continue into 2027, 2027, but, you know, sometime in 2027 we'll reach a certain level of scale where, you know, incremental growth profit that we've been reinvesting back into the business is going to start to drop down to the bottom line. We're going to stop to get leverage on the screening side of the business. So, yeah, we look at 2027 for screening as starting to sort of reduce the cash burn in the second half of the year. So that's going to get us to free cash flow break even in Q4. You know, the biggest upside we have to that is ADLT for Garden 360. You know that when we set that target, we didn't include ADLTA assumption. I think when that comes, it's just going to give us even more confidence that we get the Q4 potentially earlier. And I know you put out that, you know, first half of next year target for ADLTE. I mean, is there any risk it could slip or how do you think about it? No, we don't believe there's any risk. it could slip you know it's um it's a relatively simple application i think our you know our sort of uh base case is uh april the first and that's based on what we saw with shield she'll get an fda approval in august and then the adlt went into effect uh first of april of following year so with garnet 360 we got the fda approval in in july so we think a similar timeline and then just thinking about channel a little bit i mean you have a quest partnership so you've also you know partnered up in some cases as we think about non-oncology applications i mean how do you think about channel needs there maybe just talk a little bit about you know investments in the channel yeah we believe like you know once we have a scaled pcp channel that's highly leverageable and a bunch of testing opportunities that we are looking at and we are prioritizing are going to be toward pcps so we are very excited about that opportunity but again this is kind of research on pipeline. It's not a very near-term commercial opportunity, but we are excited with what we see. And the returns on the DTC you're spending now, have those been kind of in line with what you've envisioned? Actually, it was better than what we thought. Now, a good fraction of the cases, you know, based on some of the market research that we've done, we look at the whole funnel, top of the funnel from impression website all the way to bottom of the tunnel, that what fraction of shield orders are consumer initiated and now a material fraction are consumer initiated with some of the early innings and early investments that we've done on DTC that's why we are going to scale it as we go to 2027 great uh we're at time we'll leave it at that thanks thanks thank you
- Company
- GUARDANT HEALTH INC
- Keywords
- GUARDANT HEALTH INC